PURPOSE: In this cross-sectional pilot study we set out to discover a non-invasive biomarker that could distinguish steroid-resistant nephrotic syndrome (SRNS) from steroid-sensitive nephrotic syndrome (SSNS). EXPERIMENTAL DESIGN: Urine and clinical data were collected from patients with idiopathic nephrotic syndrome and healthy controls. Using SELDI-TOF-MS, we identified an 11-fold upregulated 13.8 kDa fragment of α 1-B glycoprotein (A1BG) in urine in SRNS. To validate our findings, A1BG was detected by Western blot. Creatinine was measured and transformed to glomerular filtration rate (GFR) by the new Schwartz formula and classified to chronic kidney disease (CKD) stage. p-Values were determined by unpaired t-test and Mann-Whitney rank sum test. Microalbumin was also measured to determine albumin/creatinine ratios. RESULTS: The 13.8 kDa A1BG was present in 7 of 19 patients with SRNS; but absent in all SSNS (n=15) and controls (n=10). The A1BG(+) patients had lower GFR than A1BG(-) patients (p<0.009) and tended to have higher CKD stage. CONCLUSION AND CLINICAL RELEVANCE: The 13.8 kDa A1BG fragment had a high discriminatory power for steroid resistance in pediatric nephrotic syndrome, but is only present in a subset of patients. Additional longitudinal studies are required to determine the usefulness of this biomarker as a non-invasive predictive marker of therapeutic response.
PURPOSE: In this cross-sectional pilot study we set out to discover a non-invasive biomarker that could distinguish steroid-resistant nephrotic syndrome (SRNS) from steroid-sensitive nephrotic syndrome (SSNS). EXPERIMENTAL DESIGN: Urine and clinical data were collected from patients with idiopathic nephrotic syndrome and healthy controls. Using SELDI-TOF-MS, we identified an 11-fold upregulated 13.8 kDa fragment of α 1-B glycoprotein (A1BG) in urine in SRNS. To validate our findings, A1BG was detected by Western blot. Creatinine was measured and transformed to glomerular filtration rate (GFR) by the new Schwartz formula and classified to chronic kidney disease (CKD) stage. p-Values were determined by unpaired t-test and Mann-Whitney rank sum test. Microalbumin was also measured to determine albumin/creatinine ratios. RESULTS: The 13.8 kDa A1BG was present in 7 of 19 patients with SRNS; but absent in all SSNS (n=15) and controls (n=10). The A1BG(+) patients had lower GFR than A1BG(-) patients (p<0.009) and tended to have higher CKD stage. CONCLUSION AND CLINICAL RELEVANCE: The 13.8 kDa A1BG fragment had a high discriminatory power for steroid resistance in pediatric nephrotic syndrome, but is only present in a subset of patients. Additional longitudinal studies are required to determine the usefulness of this biomarker as a non-invasive predictive marker of therapeutic response.
Authors: Maryam Afkarian; Manoj Bhasin; Simon T Dillon; Manuel C Guerrero; Robert G Nelson; William C Knowler; Ravi Thadhani; Towia A Libermann Journal: Mol Cell Proteomics Date: 2010-05-28 Impact factor: 5.911
Authors: Robert P Woroniecki; Ibrahim F Shatat; Katarina Supe; Zhongfang Du; Frederick J Kaskel Journal: Am J Nephrol Date: 2007-10-03 Impact factor: 3.754
Authors: Giovanni Candiano; Luca Musante; Maurizio Bruschi; Andrea Petretto; Laura Santucci; Piero Del Boccio; Barbara Pavone; Francesco Perfumo; Andrea Urbani; Francesco Scolari; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2006-09-27 Impact factor: 10.121
Authors: Claas H Hinze; Michiko Suzuki; Marisa Klein-Gitelman; Murray H Passo; Judyann Olson; Nora G Singer; Kathleen A Haines; Karen Onel; Kathleen O'Neil; Earl D Silverman; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner Journal: Arthritis Rheum Date: 2009-09
Authors: Inge Mertens; Hanny Willems; Elisabet Van Loon; Karin Schildermans; Kurt Boonen; Geert Baggerman; Dirk Valkenborg; Wilfried Gwinner; Dany Anglicheau; Marie Essig; Pierre Marquet; Maarten Naesens Journal: Kidney Int Rep Date: 2020-06-29
Authors: Michael R Bennett; LaTawnya Pleasant; Christopher Haffner; Qing Ma; Wendy D Haffey; Jun Ying; Michael Wagner; Kenneth D Greis; Prasad Devarajan Journal: Biomark Insights Date: 2017-03-08
Authors: Florent Clerc; Karli R Reiding; Bas C Jansen; Guinevere S M Kammeijer; Albert Bondt; Manfred Wuhrer Journal: Glycoconj J Date: 2015-11-10 Impact factor: 2.916